@__Con_ Lastly - dftx and CMPS in particular are very close to releasing phase III data which if goes well would take theme extremely close to taking products to market.
Block buster status could garner M&A interest from the big players who need to refill their own pipelines.
@__Con_ Furthermore. These companies are catching momentum and attention from hedge funds which tend to be fast and fluid movers of attractive themes. I believe these drugs/compounds are the key to solving a lot of mental illness and a lot of early data backs it up.
@StonkChris both halves of brain this past week:
- this market sucks and I’ve poorly executed
- you’re still up on the week why you being a whiny bitch
I increasingly feel about psychedelic medicine the way many people felt about AI a decade ago.
The science is real.
The clinical results are exceptional.
The first approvals are right around the corner.
These therapies will positively impact far more lives than most people currently expect.
Yet most investors are paying little to no attention.
The gap between what is happening and what is being priced in is extraordinary.
History suggests these disconnects rarely last forever.